Literature DB >> 15452756

Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. How important is quality of life?

Nick Bansback1, Sue Ward, Jon Karnon.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452756     DOI: 10.1007/s10198-004-0226-5

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


× No keyword cloud information.
  5 in total

Review 1.  The role of modelling in prioritising and planning clinical trials.

Authors:  J Chilcott; A Brennan; A Booth; J Karnon; P Tappenden
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

2.  Biliary stents in malignant obstructive jaundice due to pancreatic carcinoma: a cost-effectiveness analysis.

Authors:  Miguel R Arguedas; Gustavo H Heudebert; Aaron A Stinnett; C Mel Wilcox
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

3.  Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK.

Authors:  Mike Aristides; Michael Lees; Nick Botwood; Jan McKendrick; Deborah A Stephenson; Nikos Maniadakis
Journal:  Eur J Health Econ       Date:  2003-07-01

Review 4.  Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis.

Authors:  P Tappenden; J B Chilcott; S Eggington; J Oakley; C McCabe
Journal:  Health Technol Assess       Date:  2004-06       Impact factor: 4.014

5.  Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials.

Authors:  J A O'Shaughnessy; R E Wittes; G Burke; M A Friedman; J R Johnson; J E Niederhuber; M L Rothenberg; J Woodcock; B A Chabner; R Temple
Journal:  J Clin Oncol       Date:  1991-12       Impact factor: 44.544

  5 in total
  1 in total

Review 1.  Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review.

Authors:  Mahdi Gharaibeh; J Lyle Bootman; Ali McBride; Jennifer Martin; Ivo Abraham
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.